Covid-19 vaccines persevere in efficacy against Delta variant

Getting two jabs of the Covid-19 vaccines stands as an impeccable method to shield oneself from the disease. A measure which was first identified in India, which later got adapted by the UK.

The Oxford University manufactured AstraZeneca jab exhibits relatively lower efficacy in the initial phase, but offers commendable protection from the Covid-19 ailment, resembling the Pfizer-BioNTech jab after a period of four to five months, according to a study which was aimed at assessing the efficacy of the vaccines. The Moderna vaccine was however kept out of the study due to lack of data.

“The vaccines are almost certainly at least as good as the others”, researchers claimed post the completion of the study.

The Oxford University and Office for National Statistics led a household survey in the UK, titled ‘Covid-19 Household-Infection Survey’. The research volunteers analysed two and a half million test results from around 743,526 people who were part of the survey.

Pfizer BioNTech vaccine displays a whopping efficacy of 93% against the Covid infections, while AstraZeneca has marked an efficacy of 71%. Over time, there was a drop in Pfizer-BioNTech vaccine’s efficacy while that of AstraZeneca was hooked on the same. Professor Sarah Walker, an expert at Oxford University said, “when you start very very high, you have a long way to go”.

“The World Health Organization had set the bar for vaccine efficacy at 50% and we are far above that. Hence there are no grounds for worrying”, she added.

Both the vaccines are combating the Delta Variant competently.